250mg Gefitinib Tablets IP

Keeping in mind the ever-evolving requirements of our prestigious clients, we are offering 250mg Gefitinib Tablets IP. These tablets are suitable for non-small cell lung cancer (NSCLC) harboring activating EGFR mutations, tyrosine kinase inhibitors. Our offered 250mg Gefitinib Tablets IP are processed in accordance with medical standards. We are giving these tablets in diverse packaging options as per the needs of customers.